盖莱克-3在慢性肝病患者的心脏功能障碍的识别中优于N-终端Pro-B型尿素:来自前性队列的证据
Mahak Lamba1, Deepak Bhagchandani1, Ambuj Yadav1
1Department of Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India.
Annals of African medicine
|February 21, 2026
概括
加勒-3比NT-proBNP更准确的生物标志物,用于检测慢性肝病 (CLD) 患者的心脏功能障碍. 这一发现有助于早期识别和风险分层的肝硬化心肌病 (CCM).
科学领域:
- 心脏病学 心脏病学
- 肝病学 肝病学是一种肝病学.
- 生物标志物研究 生物标志物研究
背景情况:
- 循环性心肌病变 (CCM) 是慢性肝病 (CLD) 的常见并发症,常常伴有透支功能障碍.
- 使用N-终端亲B型尿素 (NT-proBNP),但由于肝硬化中的混因素而受到限制.
- 纤维化和炎症的标志物加勒-3是一种潜在的替代生物标志物.
研究的目的:
- 为了比较Galectin-3和NT-proBNP在识别CLD患者心脏功能障碍方面的诊断性能.
- 评估这些生物标志物与心声回声学参数的相关性.
主要方法:
- 这是一项对280名患有CLD的成年人进行的横截面研究.
- 综合性心声回声和生物标志物测试 (盖莱克-3,NT-proBNP).
- 通过ROC曲线,灵敏度,特异性和多变量回归评估的诊断准确性.
主要成果:
- 患有心脏功能障碍的患者中,加勒-3水平显著更高.
- 与NT-proBNP (精度为79.8%) 相比,加勒-3的诊断准确度更高 (AUC为0.97).
- 盖莱克-3与弹射率等心声学参数的相关性更强.
结论:
- 盖列-3是一种比NT-proBNP更准确的生物标志物,用于诊断CLD中的心脏功能障碍.
- 加勒-3有助于早期检测和风险分层的肝硬化心肌病 (CCM).
- 将galactin-3纳入临床实践可能会改善CCM的管理.
相关概念视频
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
631
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
631
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
225
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
225
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
550
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
550
01:30Acute Coronary Syndrome III: Diagnostic Studies
316
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
316
01:26Heart Failure III: Clinical Manifestations
685
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
685